Afficher la notice abrégée

dc.contributor.authorÁlvarez Mercado, Ana Isabel 
dc.contributor.authorRojano-Alfonso, Carlos
dc.contributor.authorMicó-Carnero, Marc
dc.contributor.authorCaballeria Casals, Albert
dc.contributor.authorPeralta, Carmen
dc.contributor.authorCasillas-Ramírez, Araní
dc.date.accessioned2024-11-21T08:21:19Z
dc.date.available2024-11-21T08:21:19Z
dc.date.issued2021-06-01
dc.identifier.citationÁlvarez Mercado, A.I. et. al. Front. Cell Dev. Biol. 9:670273. [https://doi.org/10.3389/fcell.2021.670273]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/97164
dc.description.abstractVisceral obesity is an important component of metabolic syndrome, a cluster of diseases that also includes diabetes and insulin resistance. A combination of these metabolic disorders damages liver function, which manifests as non-alcoholic fatty liver disease (NAFLD). NAFLD is a common cause of abnormal liver function, and numerous studies have established the enormously deleterious role of hepatic steatosis in ischemiareperfusion (I/R) injury that inevitably occurs in both liver resection and transplantation. Thus, steatotic livers exhibit a higher frequency of post-surgical complications after hepatectomy, and using liver grafts from donors with NAFLD is associated with an increased risk of post-surgical morbidity and mortality in the recipient. Diabetes, another MetS-related metabolic disorder, also worsens hepatic I/R injury, and similar to NAFLD, diabetes is associated with a poor prognosis after liver surgery. Due to the large increase in the prevalence of MetS, NAFLD, and diabetes, their association is frequent in the population and therefore, in patients requiring liver resection and in potential liver graft donors. This scenario requires advancement in therapies to improve postoperative results in patients suffering from metabolic diseases and undergoing liver surgery; and in this sense, the bases for designing therapeutic strategies are in-depth knowledge about the molecular signaling pathways underlying the effects of MetS-related diseases and I/R injury on liver tissue. A common denominator in all these diseases is autophagy. In fact, in the context of obesity, autophagy is profoundly diminished in hepatocytes and alters mitochondrial functions in the liver. In insulin resistance conditions, there is a suppression of autophagy in the liver, which is associated with the accumulation of lipids, being this is a risk factor for NAFLD. Also, oxidative stress occurring in hepatic I/R injury promotes autophagy. The present review aims to shed some light on the role of autophagy in livers undergoing surgery and also suffering from metabolic diseases, which may lead to the discovery of effective therapeutic targets that could be translated from laboratory to clinical practice, to improve postoperative results of liver surgeries when performed in the presence of one or more metabolic diseases.es_ES
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidades (Project Grant RTI2018-095114- B-I00) Madrid, Spaines_ES
dc.description.sponsorshipEuropean Union (Fondos FEDER, “una manera de hacer Europa”)es_ES
dc.description.sponsorshipCERCA Program/Generalitat de Catalunyaes_ES
dc.description.sponsorshipthe Secretaria d’ Universitats I Recerca del Departament d’ Economia I Coneixement (Project Grant 2017_SGR_551) Barcelona, Spain, by the COST action Programs CA17103 (DARTER), CA17112 (PRO-EURO-DILI-NET), CA17121 (COMULIS), and CA17126 (TUMIEE)es_ES
dc.description.sponsorshipConsejo Nacional de Ciencia y Tecnología (CONACYT), Fondo Sectorial de Investigación para la Educación (Project grant 257743), Méxicoes_ES
dc.description.sponsorshipFCT (Fundació Catalana de trasplantament), Spaines_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectautophagyes_ES
dc.subjectmetabolic syndromees_ES
dc.subjectischemia-reperfusiones_ES
dc.titleNew Insights Into the Role of Autophagy in Liver Surgery in the Setting of Metabolic Syndrome and Related Diseaseses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3389/fcell.2021.670273
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 4.0 Internacional